Pulmatrix (PULM) Total Liabilities (2014 - 2026)
Pulmatrix (PULM) posted Total Liabilities of $905000.0 for Q1 2026, up 175.08% sequentially from $329000.0 in Q4 2025, and little changed YoY from $904000.0 in Q1 2025.
Pulmatrix (PULM) Total Liabilities (2014 - 2026) Analysis & Trends
Pulmatrix has reported Total Liabilities for 13 years, with the latest figure at $905000.0 in Q1 2026.
- Quarterly Total Liabilities changed 0.11% year-over-year to $905000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $905000.0 (changed 0.11% YoY) and the FY2025 annual result came in at $329000.0, down 66.97% from the prior year.
- Total Liabilities advanced to $905000.0 in Q1 2026 per PULM's latest filing, from $329000.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $16.9 million in Q3 2023 and troughed at $249000.0 in Q3 2025.
- A 5-year average of $6.6 million and a median of $7.9 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities surged 62.16% in 2023, then tumbled 96.51% in 2024.
- Over 5 years, Total Liabilities stood at $9.8 million in 2022, then jumped by 62.16% to $16.0 million in 2023, then slumped by 93.76% to $996000.0 in 2024, then tumbled by 66.97% to $329000.0 in 2025, then surged by 175.08% to $905000.0 in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $905000.0, $329000.0, and $249000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 10.03 Bn |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - | 689,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 689,000.00 |
| Mar 31, 2026 | 905,000.00 |
| Dec 31, 2025 | 329,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 548,000.00 |
| Mar 31, 2025 | 904,000.00 |
| Dec 31, 2024 | 996,000.00 |
| Sep 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 2.47 Mn |
| Mar 31, 2024 | 11.37 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 16.89 Mn |
| Jun 30, 2023 | 7.94 Mn |
| Mar 31, 2023 | 9.05 Mn |
| Dec 31, 2022 | 9.84 Mn |
| Sep 30, 2022 | 11.40 Mn |
| Jun 30, 2022 | 10.96 Mn |
| Mar 31, 2022 | 11.55 Mn |
| Dec 31, 2021 | 11.37 Mn |
| Sep 30, 2021 | 10.56 Mn |